Optimizing oral absorption of peptides using prodrug strategies

• Published in: Journal of controlled release 1999-11, Vol.62 (1-2), p.231-238
• Main Author: Borchardt, Ronald T
• Format: Article
• Language: English
• Subjects: Administration, Oral; Biological and medical sciences; Caco-2 Cells; Cyclic peptide drugs; Endorphins - pharmacokinetics; Enkephalin, Leucine - pharmacokinetics; Enkephalin, Leucine-2-Alanine - pharmacokinetics; Humans; Intestinal Absorption; Medical sciences; Membrane permeability; Neuropharmacology; Neurotransmitters. Neurotransmission. Receptors; Opioid peptide; Peptide delivery; Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems; Peptides - pharmacokinetics; Peptides, Cyclic - pharmacokinetics; Pharmacology. Drug treatments; Prodrugs - pharmacology
• ISSN: 0168-3659; 1873-4995
• DOI: 10.1016/S0168-3659(99)00042-5

Prodrug strategies applied to peptides have tended to focus on modification of a single functional group (e.g., N-terminal end). Recently, our laboratory introduced the concept of making cyclic prodrugs of peptides as a way to modify their physicochemical properties sufficiently to allow them to permeate biological barriers (i.e., intestinal mucosa). This cyclization strategy required the development of new ‘chemical linkers,’ including an acyloxyalkoxy linker, a phenylpropionic acid linker, and a coumarinic acid linker. All three chemical linkers were designed to be susceptible to esterase metabolism (slow step), leading to a cascade of chemical reactions (fast steps) that result in release of the peptide. These cyclic prodrug strategies have been applied to opioid peptides in an attempt to stabilize them to metabolism and/or improve their intestinal mucosal permeation. Specifically, we prepared acyloxyalkoxy-, phenylpropionic acid- and coumarinic acid-based cyclic prodrugs of [Leu5]-enkephalin (H-Tyr-Gly-Gly-Phe-Leu-OH) and its metabolically stable analog DADLE (H-Tyr-d-Ala-Gly-Phe-d-Leu-OH) and determined their metabolic and biopharmaceutical properties. The cyclic prodrugs of these opioid peptides were shown to have: (i) favorable physicochemical properties (e.g., increased lipophilicity) for membrane permeation; (ii) unique solution structures (e.g., β-turns) that reduce their hydrogen bonding potential; and (iii) metabolic stability to exo- and endopeptidases. The cell membrane permeation characteristics of [Leu5]-enkephalin, DADLE and the cyclic peptide prodrugs were evaluated using Caco-2 cell monolayers, a cell culture model of the intestinal mucosa. The phenylpropionic acid- and coumarinic acid-based cyclic prodrugs of [Leu5]-enkephalin and DADLE were shown to have significantly better cell permeation characteristics than the parent opioid peptides. Furthermore, these cyclic prodrugs were shown to be transcellular permeants (in contrast to the opioid peptides, which are paracellular permeants), and were not substrates for polarized efflux systems. Surprisingly, the acyloxyalkoxy-based prodrugs of [Leu5]-enkephalin and DADLE were shown to exhibit very low permeation through Caco-2 cell monolayers, which could be attributed to their substrate activity for efflux systems.